Načítá se...
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia
Rapid development of the small molecule proteasome inhibitor bortezomib has yielded important clinical benefit for patients with multiple myeloma. Early phase clinical trials suggest the agent has similar efficacy in Waldenströms Macroglobulinemia. Optimization of bortezomib-based therapy, though, r...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2009
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3133638/ https://ncbi.nlm.nih.gov/pubmed/19452315 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428190902866732 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|